Medical research

FDA approves immunotherapy for dMMR endometrial cancer

The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment ...

Medications

Study: Copanlisib + rituximab slows relapsed indolent lymphoma

Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association ...

Medications

Tislelizumab plus chemo slows advanced squamous NSCLC

(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...

Oncology & Cancer

New study looks at long-term outcomes and costs of NMIBC

A new research study leveraging a database from the largest equal access health system in the US, the Department of Veteran Affairs, offers insight into the outcome of specific treatment patterns for advanced bladder cancer ...

page 1 from 40